PMV Pharma says rezatapopt posts 46% response rate in Phase 2 platinum-resistant ovarian cancer trial

PMV Pharmaceuticals reported updated interim Phase 2 PYNNACLE results for rezatapopt in platinum-resistant or refractory ovarian cancer.

• Results were already released from a May 14, 2026 cutoff; broader cohort updates are scheduled for a fourth-quarter 2026 medical conference.
• Patients showed meaningful tumor shrinkage with durable benefit, supporting the drug’s potential as a monotherapy in this hard-to-treat setting.
• Safety remained broadly consistent across cohorts, with most side effects described as mild to moderate.
• FDA feedback backed an accelerated-approval filing strategy; an NDA submission is planned for the first quarter of 2027.